ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - elotuzumab - אבקה להכנת תמיסה מרוכזת לעירוי - elotuzumab 300 mg/vial - elotuzumab

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - elotuzumab - אבקה להכנת תמיסה מרוכזת לעירוי - elotuzumab 400 mg/vial - elotuzumab

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - nivolumab; relatlimab - תרכיז להכנת תמיסה לאינפוזיה - relatlimab 4 mg/ml; nivolumab 12 mg/ml - nivolumab

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - mavacamten - קפסולות - mavacamten 10 mg - mavacamten

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - mavacamten - קפסולות - mavacamten 15 mg - mavacamten

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - mavacamten - קפסולות - mavacamten 2.5 mg - mavacamten

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - mavacamten - קפסולות - mavacamten 5 mg - mavacamten

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - deucravacitinib - טבליות מצופות פילם - deucravacitinib 6 mg - deucravacitinib

ישראל - עברית - Ministry of Health

bristol - myers squibb, israel - entecavir; entecavir - טבליות מצופות פילם - entecavir 0.5 mg; entecavir 0.5 mg - entecavir - entecavir - baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. this indication is based on clinical trial data in patients with hbeag positive and hbeag negative hbv infection, nucleoside naive patients and patients with lamivudine-refractory hepatitis b.decompensated liver disease.

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited - entecavir 1 mg - film coated tablets - entecavir - baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. this indication is based on clinical trial data in patients with hbeag positive and hbeag negative hbv infection, nucleoside naive patients and patients with lamivudine-refractory hepatitis b.decompensated liver disease.